MJP Associates Inc. ADV Acquires 217 Shares of Eli Lilly and Company (NYSE:LLY)

MJP Associates Inc. ADV boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 6.6% in the fourth quarter, Holdings Channel reports. The firm owned 3,497 shares of the company’s stock after acquiring an additional 217 shares during the period. MJP Associates Inc. ADV’s holdings in Eli Lilly and Company were worth $2,700,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. FPC Investment Advisory Inc. grew its stake in shares of Eli Lilly and Company by 358.3% during the fourth quarter. FPC Investment Advisory Inc. now owns 55 shares of the company’s stock valued at $45,000 after purchasing an additional 43 shares during the last quarter. Prudent Man Investment Management Inc. acquired a new stake in Eli Lilly and Company in the 4th quarter valued at about $48,000. Compass Financial Services Inc bought a new stake in Eli Lilly and Company in the 4th quarter valued at $50,000. Fiduciary Advisors Inc. bought a new position in shares of Eli Lilly and Company in the fourth quarter worth $58,000. Finally, Bellwether Advisors LLC bought a new stake in shares of Eli Lilly and Company during the 4th quarter valued at approximately $66,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on LLY. Wells Fargo & Company reaffirmed an “overweight” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Berenberg Bank set a $970.00 price objective on Eli Lilly and Company in a report on Thursday, January 16th. Guggenheim reissued a “buy” rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price objective for the company from $892.00 to $888.00 in a report on Tuesday, April 8th. Finally, HSBC cut shares of Eli Lilly and Company from a “buy” rating to a “reduce” rating and reduced their price objective for the company from $1,150.00 to $700.00 in a research report on Monday, April 28th. One analyst has rated the stock with a sell rating, two have issued a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $1,002.80.

Insider Buying and Selling

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.13% of the stock is owned by corporate insiders.

Eli Lilly and Company Stock Down 2.0%

Shares of Eli Lilly and Company stock opened at $736.21 on Monday. The business has a 50-day moving average price of $810.98 and a 200 day moving average price of $810.32. The firm has a market cap of $697.73 billion, a P/E ratio of 62.87, a P/E/G ratio of 1.40 and a beta of 0.48. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a fifty-two week low of $677.09 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $4.64 by ($1.30). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. The firm had revenue of $12.73 billion for the quarter, compared to analyst estimates of $12.77 billion. During the same quarter in the prior year, the firm earned $2.58 EPS. The firm’s revenue was up 45.2% compared to the same quarter last year. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be paid a dividend of $1.50 per share. The ex-dividend date of this dividend is Friday, May 16th. This represents a $6.00 annualized dividend and a yield of 0.81%. Eli Lilly and Company’s dividend payout ratio is 48.82%.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.